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Abstract
Background Characterizing expression profiles of
different immune checkpoint molecules are promising
for personalized checkpoint inhibitory immunotherapy.
Gliomas have been shown as potential targets for immune
checkpoint inhibitors recently. Our study was performed
to determine coexpression levels of two major B7 immune
regulatory molecules programmed death ligand 1 (PD-L1)
and B7-H4, both of which have been demonstrated to
inhibit antitumor host immunity in gliomas.
Methods We assessed tumor tissues from stage II–IV
primary gliomas (n=505) by immunohistochemistry
(IHC) for protein levels of both PD-L1 and B7-H4. Gene
coexpression analysis assessing clusters based on
extent of PD-L1/B7-H4 classifier genes expression were
investigated in two transcriptome datasets (The Cancer
Genome Atlas and Chinese Glioma Genome Atlas). In
addition, levels of immune cell infiltrates were estimated
with IHC and RNA-seq data for assessing the tumor
immune microenvironment of PD-L1/B7-H4 subgroups.
Results High expression of PD-L1 and B7-H4 in gliomas
was 23% and 20%, respectively, whereas coexpression of
two proteins at high levels was limited to 2% of the cases.
Comparable results were seen in RNA-seq datasets where
PD-L1 mRNA expression levels negatively correlated with
that of B7-H4. Gene coexpression modules clustered
within each grade of gliomas demonstrated lack of double-
high modules (cluster with high expression of both PD-L1
and B7-H4 classifier genes). B7-H4 mRNA expression
levels showed negative correlation with extent of immune
cell infiltration and High-B7-H4 module gliomas (high B7-
H4 but low PD-L1 classifier genes expression) had less
tumor-infiltrating lymphocytes (TILs) and tumor-associated
macrophages (TAMs). IHC assessment also showed few
TILs and TAMs in High-B7-H4 subgroup gliomas.
Conclusions The majority of gliomas express PD-L1 or
B7-H4, however, coexpression of both at high levels is
minimal. The high-B7-H4 patients could be considered as
‘super-cold’ gliomas with significantly deficient in TILs,
suggesting that B7-H4 might inhibit T-cell trafficking into
the central nervous system. This study demonstrated that
PD-L1 and B7-H4 may serve as mutually compensatory
immune checkpoint molecules in gliomas for immune
targeted or active-specific immunotherapy. The distinct
B7-H4 pathways modulating T-cell function and immune
evasion in glioma patients deserved to be further explored
in the future during immunotherapy.

Background
Tumor immunotherapy has shown significant
breakthroughs in recent years, particularly
with the approval of immune checkpoints
inhibitors (ICIs) and T-cell therapy.1 Studies
with ICIs have demonstrated durable clinical
responses and prolonged survival in various
solid tumors such as melanoma, targeting
programmed death 1 (PD-1) and programmed
death ligand 1 (PD-L1) molecules.2 Since the
dogma that the central nervous system (CNS)
is an immune-
privileged site for tumors
has been challenged with recent immune
profiling studies, immunotherapy has been
used more frequently to treat gliomas, the
most common and lethal tumor in the CNS.3
Although the immunotherapy has increasing
appeal for the treatment of cancer, only a
fraction of specific cancer type patients has
overall long-
term survival benefits.2 4 Clinically, useful immune-related biomarkers are
needed to define which patients will benefit
and to triage patients into optimal immunotherapy protocols.
The PD-L1 expression in tumor microenvironment (TME) has been considered as a
predictive biomarker for anti-
PD-1/PD-
L1
therapies. High PD-L1 expression in patients
was correlated with high response rate for
PD-1/PD-L1 blockade.5 6 Nevertheless, therapeutic resistance in patients with high PD-L1
expression and immunotherapy-
insensitivity
in those with low PD-
L1 expression necessitate characterization of additional immunosuppressive biomarkers and a deeper
understanding of immune escape mechanisms.7 Previous studies demonstrated that
the majority of gliomas were PD-L1 positive
but only a small number of patients had high
expression.8 9 Despite various clinical trials
with PD-1/PD-L1 inhibitors in gliomas, the
utility and reliability of PD-L1 as an immunosuppressive biomarker remains insufficient.3
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B7-H4 (B7x /B7S1) is one of the T-cell costimulatory
and coinhibitory B7 family molecules overexpressed in
various malignant tumors, including gliomas.10 We have
recently reported that B7-
H4 expression is associated
with glioma grade and clinical outcome.11 In addition,
blockade of B7-H4 has been shown to enhance T-cell
activation.12 In our previous study, we demonstrated
that B7-H4 activation in glioma associated macrophage/
microglia establishes a cross-talk with glioma stem cells,
which leads to immunosuppression.11 Considering
mutual exclusive expression of PD-L1 and B7-H4 in lung
cancer13–15 and breast cancer,16 and that glioblastoma
multiforme (GBM) patients with low expression of B7-H4
benefited from dendritic cell (DC) vaccine,4 we speculated that B7-H4 may be another promising biomarker
for immunotherapy in glioma patients as a supplement
for PD-L1. Nevertheless, the relationship between PD-L1
and B7-H4 in gliomas remains unexplored.
In this study, using immunohistochemistry (IHC), we
evaluated protein levels of PD-L1 and B7-H4 in a large
glioma patient cohort in order to determine their coexpression status. Two transcriptomics datasets with mRNA
expression were also used to investigate the relationship
between PD-L1 and B7-H4 by correlation and gene coexpression module analyzes. To a significant extent, we
found limited coexpression of PD-L1 and B7-H4, which
indicates that the PD-L1 alone is not sufficient to define
immune evasion strategy in gliomas and that B7-H4 is
also a significant component of the immune escape
mechanism.

Methods
Specimens and tissue microarrays
Archival FFPE (formalin fixed paraffin embedded) tumor
tissue sections were obtained from patients diagnosed
with primary gliomas(n=505) when undergone tumor
resection between 2001 and 2017 at the Department
of Neurosurgery, Huashan Hospital, Fudan University.
Three FFPE tissue microarrays (TMA) sections including
276 samples were prepared using 1.5 mm tissue cores, and
the other 229 specimens were overlapped as described
previously.4 The tumor area for each core in TMA was
confirmed by the neuropathologist using HE staining.
Detailed clinicopathological characteristics are available
in online supplementary table S1 (online supplementary
additional file 2: table S1).
Immunohistochemistry
FFPE glioma tumor tissue sections were deparaffinized in
xylene and rehydrated through a graded series of ethanol
concentrations; the sections were blocked with 3% H2O2
for 20 min at room temperature. Sections for B7-H4 and
CD3 were retrieved by Tris-Ethylene Diamine Tetraacetie
Acid (EDTA, pH=9.0) and sodium citrate buffer (pH=6.0)
respectively, and sections for PD-
L1 and CD163 were
retrieved by lycium hydrochloric acid (pH=6.0). B7-H4
antibody (Ab), PD-L1 Ab and CD3 Ab were diluted at
2

the same dilution of 1:100, while CD163 Ab was diluted
at 1:50. After incubated overnight at 4℃, primary Abs
were washed out and followed by VECTASTAIN ABC
kit (PK-6200) for 30 min. DAB substrate kit (SK4100)
was used to develop DAB chromogen and Hematoxylin
staining solution was used to stain nuclei. The PD-L1,
CD3 and CD163 Abs have been validated in gliomas by
previous studies (online supplementary additional file
2: table S2). For B7-H4 Ab, GL261 cells transfected with
human B7-H4 gene were prepared as FFPE cell blocks
(online supplementary additional file 4: supplementary
materials and methods, additional file 1: figure S1); IHC
was performed with or without primary Ab as positive and
negative controls, respectively. FFPE cell blocks derived
from GL261 cells transfected with an empty vector were
used for negative controls. B7-H4-positive GL261 cells
showed brownish stain while cells in negative controls
were stained with hematoxylin showing blue nuclei
(online supplementary additional file 1: figure S1). Moreover, the staining in normal control brain tissues (non-
tumor tissues) with primary Abs (online supplementary
additional file 1: figure S1) and in the tumor tissue
sections without primary Abs were conducted as negative
controls for each targeted protein.
Manual quantification of IHC
B7-H4 and PD-L1 specific IHC staining was semiquantitatively scored based on the intensity and percentage as
previously described.4 11 Briefly, the cells with partial or
complete IHC staining at any intensity are considered
as positive cells. The positive reaction of B7-H4/PD-L1
was scored into four grades according to the intensity of
the staining: 0, 1, 2 and 3. The percentages of B7-H4/
PD-L1–positive cells were also scored into four categories: 0 (0%), 1 (1%–33%), 2 (34%–66%) and 3 (67%–
100%). The sum of the intensity and percentage scores
was used as the final IHC score from 0 to 6. The staining
pattern of the tissues was defined as follows according
to the final IHC score: low expression, 0–2; high expression, 3–6. Extent of TIL presence in TMA slide cores was
assessed by semiquantitative measurement of the density
of CD3 positive (CD3+) cells, and was scored as previously
published9 17: 1, no (less than four TILs in the entire specimen) or sporadic (more than four but no accumulation)
CD3+ cells; 2, moderate numbers of CD3+ cells (single
areas with accumulation of TILs); 3, abundant occurrence of CD3+ cells (TILs throughout the tumor section);
and 4, highly abundant occurrence of CD3+ cells (high
frequency of TILs throughout the entire tumor section).
The IHC of CD163 was assessed as the percentage of positive cells related to the total cell number.
The IHC staining was analyzed by two observers blinded
to clinical characteristics. A consensus for the final scores
of PD-L1, B7-H4 and CD3 were reached for each sample,
and the mean number of positive proportions from
two observers was calculated for CD163. Representative photographs of each category for staining intensity
and percentage of PD-L1/B7-H4 were shown in online
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supplementary figure S2 (online supplementary additional file 1: figure S2). Fleiss’s kappa for the categorical
values (high expression and low expression for PD-L1/
B7-H4) and ranked numerical values (1, 2, 3 and 4 for
CD3+) were calculated for the interobserver agreement
between two observers. The correlation analysis based
on Spearman’s testing for continuous numerical values
(positive proportion for CD163+) was performed to eliminate a potential interobserver variation of manual quantification. Concordant agreements were observed for
the interobserver assessment in each protein molecule
assessed (online supplementary additional file 2: table S3
and S4).
Transcriptome data analysis
Two published glioma transcriptome datasets were
downloaded from The Cancer Genome Atlas (TCGA)
and Chinese Glioma Genome Atlas (CGGA).18 19 RNA
sequencing (RNA-
seq) expression data were further
normalized using upper quartile FPKM (FPKM-
UQ)
as described in TCGA website. The RNA-seq data were
log2 transformed before analysis between several groups.
Patient demographics were obtained from each data
portal. Differentially expressed genes (DEGs) between
different groups were identified using DESeq2 package20
with the criteria of |fold change|>2 and the false discovery
rate <0.05).
Prediction of PD-L1/B7-H4 classifier genes and clustering
analysis
In order to identify PD-L1/B7-H4 classifier genes (genes
that are coexpressed with PD-L1 or B7-H4) in the training
dataset (TCGA), we used biweight midcorrelation (bicor)
to evaluate ‘similarity’ between gene expression profiles,
which is thought to be a good measurement for gene
coexpression module analysis.21 First, bicor for each pair
of genes was calculated, and the 95th percentile of the
bicor values was defined as the cut-off, which was 0.37027.
Genes whose patterns are highly correlated to PD-L1 or
B7-H4 were further selected if positively correlated with
each other (the bicor values are larger than the cut-off).
Finally, 62 PD-L1 classifier genes and 35 B7-H4 classifier
genes were determined (online supplementary additional
file 2: table S5).
We performed non-
negative matrix factorization
(NMF) algorithm with the R package NMF22 to define
glioma clusters.23 The following steps were used to determine the optimal factorization rank (the number of
clusters) in each data set: (1) Random expression data
were generated by permutating columns (patients) in the
original dataset; (2) We performed 100 runs of NMF and
select the best fitted model for both the original and the
corresponding random data sets with rank from 2 to 7,
and obtained the residual sum of squares (RSS) for each
rank; (3) The smallest rank was selected if RSS decrease
is less than that in random data as described previously.24 With the optimal rank k, the partitioning around
medoids algorithm was used to perform clustering on the
Chen D, et al. J Immunother Cancer 2020;8:e000154. doi:10.1136/jitc-2019-000154

coefficient matrix of each run of the corresponding NMF
model where the number of clusters is k. The consensus
matrix of clustering was then generated and the final
clusters of samples were determined by cutting the hierarchical clustering of the consensus matrix into k groups.
Bioinformatic analysis
The R package ESTIMATE (Estimation of STromal and
Immune cells in MAlignant Tumour tissues using Expression data) was applied to predict tumor purity based on
the estimation of stromal and immune scores in tumor
tissues using gene expression data.25 Samples from TCGA
having genomic sequencing data were labeled with
ABSOLUTE purity instead of ESTIMATE purity and were
extracted from previous paper.26 The gene set variation
analysis (GSVA) package of R was used to calculate infiltrating scores for 22 immune cell subtypes and microglia.27
In order to rule out possible bias from different algorithms, we calculated absolute immune cell fractions for
22 immune cell populations with CIBERSORT (Cell-type
Identification By Estimating Relative Subsets Of RNA
Transcripts),28 followed by being corrected using tumor
purity per sample.29 Gene ontology (GO) term enrichment analysis was carried out with R language using clusterProfiler packages.30 Two gene sets extracted from the
Molecular Signatures Database (immune system process,
M13664; immune response M19817) were used to profile
immune phenotype between modules using principal
components analysis (PCA).31 Ontology gene sets were
obtained from MSigDB32 and the results of gene set
enrichment analysis (GSEA) were visualized by cluster
Profiler package.30
Statistical analyses
Spearman’s rank correlation coefficient was used for
correlation analysis. χ2 test or Fisher’s exact test was
used for categorical variables and differences in continuous variables between groups were evaluated by t-test
or one-way analysis of variance. All tests were two-sided
performed by SPSS software or R language and p<0.05
was considered statistically significant labeled with *
for p<0.05, ** for p<0.01, *** for p<0.001, and **** for
p<0.0001.

Results
Assessment of PD-L1 and B7-H4 expression in gliomas
Although the majority of newly diagnosed gliomas
patients were PD-L1-positive (61%, IHC score >0) in the
IHC cohort (n=505), only 23.4% of them were defined
as high expression of PD-L1 (IHC score >2). For GBM
patients in this cohort, about 73.5% samples were PD-L1-
positive while 29.1% were determined as high expression.
For lower grade gliomas (LGG, grades II and III), we
found that 49.4% of patients expressed PD-L1 while 18.5%
expressed it at high levels. The relationship between
PD-L1 expression and clinicopathological variables were
investigated as shown in online supplementary table S6
3
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Figure 1 Coexpression with high level of both PD-L1 and B7-H4 expression was limited in the IHC cohort. Distributions of
PD-L1/B7-H4 subgroups in gliomas (A). Representative cases of PD-L1/B7-H4 subgroups were shown with the same area for
per sample: case 1, High-PD-L1 subgroup; case 2, high-B7-H4 subgroup; case 3, double-Low subgroup; case 4, double-High
subgroup (B). Magnification, ×40 objective; Bar, 20 um. PD-L1, programmed death ligand 1.

(online supplementary additional file 2: table S6). Tumor
location, histology, WHO grade and IDH gene status
had a significant correlation with PD-L1 expression. The
percentages of B7-H4-positive and B7-H4 high-expression
samples were 54.1% and 19.6% in the IHC cohort, 53.8%
and 14.1% in GBM patients, and 54.2% and 24.4% in
LGG patients, respectively. The B7-
H4 expression was
significantly associated with gender, histology, WHO
grade, TERT gene status and chromosome 1 p/19q
(Chr1p/19q) status (online supplementary additional
file 2: table S6).
PD-L1 and B7-H4 coexpression is limited in gliomas
In the cohort assessed for IHC (n=505), 61% of glioma
patients had low expression of both PD-L1 and B7-H4
(double-
low subgroup), 20% had high expression
of PD-L1 but low expression of B7-H4 (high-PD-L1
subgroup) and 17% had high expression of B7-H4 but
low expression of PD-L1 (high-B7-H4 subgroup). Interestingly, only 2% of the patients had high expression of both
PD-
L1 and B7-
H4 (double-
high subgroup, figure 1A).
Significant associations were detected in histology, WHO
grade, IDH status, TERT gene status and Chr1p/19q
status among PD-
L1/B7 H4 subgroups (online supplementary additional file 1: figure S3 and additional file
4

2: table S7). Representatives of these subgroups with
mutually exclusive expression of PD-L1 and B7-H4 are
shown in figure 1B. Moreover, H-scores of PD-L1 and
B7-H4 in TMA cores (online supplementary additional
file 4: online supplementary materials and methods) also
showed limited coexpression of both biomarkers (online
supplementary additional file 1: figure S4).
In order to avoid possible bias by tumor tissue sampling
in the TMA cores, we analyzed the mRNA expression
levels of PD-L1and B7-H4 based on two published RNA-
seq datasets obtained from TCGA and CGGA. As shown
in figure 2, a similarly restricted coexpression pattern
was observed in TCGA cohort (figure 2A, n=666) and
CGGA cohort (figure 2B, n=305) with significant negative correlation between PD-L1 and B7-H4. Moreover, we
found most other checkpoint immune molecules that
have been verified as therapeutic targets in clinical or
preclinical trials were tightly associated with PD-L1 while
demonstrating mutually exclusive expression with B7-H4
(figure 2).
Identification of PD-L1/B7-H4 classifier genes
Identification of gene coexpression modules around
key signaling pathways may enable molecular classification of gliomas. We, therefore, decided to generate
Chen D, et al. J Immunother Cancer 2020;8:e000154. doi:10.1136/jitc-2019-000154
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Figure 2 Correlation analysis between estimable checkpoint molecules in two transcriptome datasets showed mutual
exclusive expression profiles between PD-L1 and B7-H4. TCGA dataset (A). CGGA dataset (B). CGGA, Chinese Glioma
Genome Atlas; PD-L1, programmed death ligand 1; TCGA, The Cancer Genome Atlas.

gene coexpression modules by classifier genes that are
strongly associated with PD-
L1 and B7-
H4 using transcriptomics datasets. The classifier genes were extracted
from TCGA training set (n=666), identifying genes with
similar expression patterns with PD-L1 (62 genes) and
B7-H4 (35 genes), analyzes of which could help decipher
key signaling pathways related to these molecules (online
supplementary additional file 2: table S5). GO analysis
for classifier genes revealed that they were significantly
enriched in many biological processes related to immune
responses and intercellular communication (online
supplementary additional file 2: table S8).
PD-L1/B7-H4 classifier genes identified glioma subtypes
According to the expression profiles of predicted PD-L1/
B7-
H4 classifier genes, each grade of gliomas from
TCGA could be classified into three new subtypes: high-
PD-L1 (high expression of PD-L1 but low expression of
B7-H4 classifier genes), high-B7-H4 (high expression of
B7-H4 but low expression of PD-L1 classifier genes) and
double-low modules (low expression of both PD-L1 and
B7-
H4 classifier genes) (figure 3A and online supplementary additional file 1: figures S5a and S6a). Here,
we confirmed that high-
PD-
L1 module gliomas highly
expressed PD-L1 with lower levels of B7-H4 while High-
B7-
H4 module gliomas highly expressed B7-
H4 with
lower levels of PD-L1 (online supplementary additional
file 1: figures S5b, S6b and S7a). Strikingly, we found
there was no double-High module (high PD-L1 and high
B7-H4 classifier genes expression) which supported our
previous finding of a restricted coexpression pattern
between PD-L1 and B7-H4. We then used the transcriptome dataset from CGGA to validate such classification
criteria (figure 3B and online supplementary additional
file 1: figures S7-
S9). The number of possible glioma
subtypes was determined based on appropriate rank
Chen D, et al. J Immunother Cancer 2020;8:e000154. doi:10.1136/jitc-2019-000154

number with stable cophenetic correlation coefficients,
which is consistent with the above observations (online
supplementary additional file 1: figures S10-S12). In addition, most of the clinicopathological parameters exhibited statistically significant differences between different
subtypes for each grade, such as age, histology, TCGA
subtype and molecular classifications (online supplementary additional file 2: tables S9-S14). Further investigation of the relationship between new subtypes and known
TCGA subtypes revealed that almost all of the mesenchymal subtype belonged to the high-
PD-
L1 subtype,
whereas the high-B7-H4 subtype mainly were contained
in the proneural subtype.
Immune microenvironment is differentially activated in PD-L1/
B7-H4 modules
Considering that many PD-
L1/B7-
H4 classifier genes
are related to tumor–immune system interactions, it is
possible that modules defined by PD-
L1/B7-
H4 signatures may be distinct in terms of the tumor immune
microenvironment. Indeed, the immune and stromal
score calculated by ESTIMATE in TCGA set revealed that
gliomas in the High-PD-L1 module had more immune
cell infiltrations whereas a significantly smaller immune
infiltrating score was obtained for High-B7-H4 module
(figure 4A and online supplementary additional file 1:
figures S13a and S14a). We also found that high-B7-H4
module had higher tumor purity has been shown to
contribute to poor immune cell infiltration (figure 4B
and online supplementary additional file 1: figures S13b
and S14b). The GSVA score represented the extent of 23
immune cells infiltrations suggested smaller fractions of
TILs and tumor-associated macrophages (TAMs) in the
high-B7-H4 module (figure 4C and online supplementary additional file 1: figures S13c and S14c). Further
evaluation of absolute fractions of different immune
5
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Figure 3 Gene coexpression modules in each glioma grade using PD-L1/B7-H4 classifier genes showed mutual exclusive
expression profiles in RNA-seq datasets without double-High modules. The appropriate numbers of clusters were determined
as mentioned in Methods (additional file 1: online supplementary additional file 1: figures S10-S12). The grade 4 gliomas in
TCGA dataset were clustered into three modules (A). The grade 4 gliomas in CGGA dataset were clustered into four modules
(additional file 1: online supplementary additional file 1: figure S33) and could be combined into three modules (B). CGGA,
Chinese Glioma Genome Atlas; PD-L1, programmed death ligand 1; TCGA, The Cancer Genome Atlas.

cell types verified that high-PD-L1 module tumors had
more TILs and TAMs than tumors of the high-B7-H4
module (online supplementary additional file 1: figures
S15a, S16a and S17a). The data from CGGA validation
dataset also showed that high-
B7-
H4 module gliomas
6

were deficient of TILs in the TME (online supplementary additional file 1: figures S15b, S16b, S17b and S18-
S20). Correlation analysis revealed that B7-H4 expression
level negatively correlates with TILs and TAMs presence
(online supplementary additional file 1: figures S21-S25).
Chen D, et al. J Immunother Cancer 2020;8:e000154. doi:10.1136/jitc-2019-000154
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Figure 4 Assessment of tumor immune microenvironment among PD-L1/B7-H4 modules in grade 4 gliomas from TCGA
dataset. ESTIMATE evaluation showed less immune infiltration in high-B7-H4 module (A). High-B7-H4 module gliomas had
higher tumor purity (B). Comparison of GSVA score representing the extent of immune cell infiltration between modules
demonstrated the reduction of immune cells in high-B7-H4 modules (C). GSVA, gene set variation analysis; PD-L1, programmed
death ligand 1; TCGA, The Cancer Genome Atlas.

We performed IHC staining of CD3 and CD163 in TMA
cores to determine the presence of TILs and TAMs in
PD-
L1/B7-
H4 subgroups, respectively, and found that
gliomas in the high-B7-H4 subgroup gliomas appeared as
‘super-cold’ tumors with less TILs and TAMs compared
with high-PD-L1 subgroup (figure 5 and online supplementary additional file 1: figure S26).
Considering such distinct levels of immune cell infiltration among PD-L1/B7-H4 modules, we explored the
differences between High-PD-L1 module and High-B7-H4
module gliomas using immune-
related gene sets and
whole genome expression data. The PCA analysis showed
remarkable differences between High-PD-L1 and High-
B7-H4 modules in immune phenotype and whole genome
expression signature for each grade gliomas (online
supplementary additional file 1: figures S27-S29). Next,
we detailed these findings with GSEA analysis between
high-PD-L1 and high-B7-H4 modules. Here, we found
Chen D, et al. J Immunother Cancer 2020;8:e000154. doi:10.1136/jitc-2019-000154

that many immune response pathways were enriched
in high-PD-L1 module gliomas, such as T-cell receptor
signaling pathway, regulation of antigen processing and
presentation, macrophage differentiation status and toll-
like receptor signaling pathway (online supplementary
additional file 1: figure S30). DEGs were obtained within
each glioma grade from two datasets, and DEGs shared
between high-PD-L1 and high-B7-H4 modules were identified (online supplementary additional file 1: figure S31
and additional file 3: table S15).
Discussion
Previous studies have shown that the majority of gliomas
expressed PD-L1 with low intensity,8 9 whereas less information is known about B7-
H4 expression landscape
in large glioma cohorts. Meanwhile, the coexpression
status of PD-
L1and B7-
H4 in gliomas is unknown. In
7
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Figure 5 Difference in TILs (CD3 positive cell) density among PD-L1/B7-H4 subgroup gliomas in TMA slides. Representative
examples of TIL infiltration with CD3+ IHC score: 1, no or sporadic CD3+ cells; 2, moderate numbers of CD3+ cells; 3, abundant
occurrence of CD3+ cells; and 4, highly abundant occurrence of CD3+ cells (A). Comparation of CD3+ IHC score showed that
High-B7-H4 subgroup gliomas had less TIL infiltration than high-PD-L1 subgroup gliomas (B). Magnification, ×20 objective;
Bar, 50 μm. IHC, immunohistochemistry; PD-L1, programmed death ligand 1; TILs, tumor-infiltrating lymphocytes; TMA, tumor-
associated macrophage.

our current study, protein levels of PD-L1 and B7-H4
were assessed in 505 glioma patients through IHC analysis. Although PD-L1 was found to be expressed in the
majority of this cohort, only 23% had a high expression
of this protein. Similarly, B7-H4 protein was detected in
>50% of glioma samples, whereby it was highly expressed
in 20% of samples. As previously reported in lung and
breast cancer,13–16 we noticed that coexpression of PD-L1
and B7-
H4 in gliomas was an infrequent event (2%).
The lack of double-high subgroup (high expression of
both PD-L1 and B7-H4) suggested that distinct immune
evasion pathways existed for the glioma subgroups in our
study. Our findings can be used as a potential strategy for
targeting these alternative immune checkpoint molecules
such as B7-H4 in subgroups with low PD-L1 expression.
The limitation of our study is that the IHC glioma
cohort was selected retrospectively from samples with
available clinical information. Insufficient tumor representation by single core in TMA samples also may have
induced bias. However, we accounted for this by verifying
the expression profiles in two different transcriptome
datasets with correlation analysis and gene coexpression
modules. Molecular classification based on stable unbiased gene expression clusters has been shown capable
of identifying intrinsic features around key signaling
pathways.23 33 Classifier genes demonstrating similar
gene expression patterns with PD-L1 and B7-H4 were
identified and shown to be enriched in immune-related
mechanisms. We believe that the PD-
L1/B7-
H4 molecules clustered by the classifier genes distinctively activate the glioma immune microenvironment. In line with
this, PD-L1/B7-H4 coexpression modules were clustered
8

without a double-high module (high expression of both
PD-
L1 and B7-
H4 classifier genes), which suggested
that the mechanisms associated with PD-L1 and B7-H4
might lead to distinct immunophenotype classification
of gliomas. We established our coexpression modules in
each glioma grades, respectively, to reduce the bias from
WHO grade in this study, which showed the limited coexpression pattern and different immune cell infiltrations
regardless of the WHO grades.
It was previously reported that PD-L1 expression and
TIL infiltration are distinguishing features for immunotherapy sensitivity.34 Classification of TME based on PD-L1
and TILs determined two major immunophenotypes—
‘hot and cold tumors’.35 Hot tumors have higher potential
to benefit from PD-1/PD-L1 blockade or other immunotherapies due to existence of tumor-specific T-cells. We
observed that high-
PD-
L1 module gliomas exhibited
more TILs compared with other PD-L1/B7-H4 modules
in our study. The mesenchymal subtype is considered to
be more responsive to immune-based therapies because of
higher number of TILs.36 Accordingly, the mesenchymal
subtype was mainly clustered in high-PD-L1 modules in
our study. Therefore, gliomas with high PD-L1 expression
or PD-L1-related pathways enrichment may potentially
benefit from PD-1/PD-L1 blockade owing to pre-existing
TILs. However, previous studies indicated that PD-L1 can
also be expressed on tumor cells as a result of oncogenic
signaling, even in the absence of TILs, which can account
for resistance to PD-1/PD-L1 ICIs immunotherapy regardless of high PD-L1 levels.35 In our study, we also observed
the presence of gliomas harboring significantly less TILs
within the high-PD-L1 module. A deeper interrogation of
Chen D, et al. J Immunother Cancer 2020;8:e000154. doi:10.1136/jitc-2019-000154
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these tumors with accurate sub clustering will be instrumental for triaging patients using PD-1/PD-L1 inhibitors.
Furthermore, in our High-PD-L1 module, we found high
expression of other immunosuppressive molecules, such
as CTLA-4, TIM3, LAG3 and IDO1, all of which showed
positive correlation with PD-L1 mRNA levels. Combination therapies with PD-1/PD-
L1 inhibitors and agents
targeting these immunosuppressive molecules may be
a promising approach towards eliminating resistance
against single-agent therapies.2
In contrast to the High-PD-L1 subgroup, high-B7-H4
gliomas were detected with less TILs and TAMs. Considering that gliomas have been labeled as ‘cold tumors’ as
a feature of primary intracranial tumors when compared
with other solid tumors,37 gliomas with high B7-
H4
expression or B7-H4-related pathways in this study may
behave as a ‘super-cold’ tumors, which are insensitive to
existing forms of glioma immunotherapies due to the
absence of specific TILs. We downloaded RNA-seq data
from two cohorts of melanoma (n=49)38 and non-small
cell lung cancer (n=21) patients treated with anti-PD-1
Abs (online supplementary additional file 4: supplementary materials and methods), both of which demonstrated
that higher B7-H4 expression levels in non-responders
were close to statistical significance (online supplementary additional file 1: figure S32). Another study also had
confirmed a negative predictive role of B7-H4 in non-
small cell lung cancer patients receiving nivolumab based
on IHC scores.39 Moreover, in our clinical trial for DC
vaccine in GBM patients, we reported no clinical response
in patients with high B7-H4 IHC score.4 The data from
clinical patients mentioned above indicated that treatment with agents targeting B7-
H4 or B7-
H4-
mediated
immune escape mechanisms may be more effective than
PD-1/PD-L1 checkpoint inhibitors or DC vaccines alone
for these tumors. However, the role of B7-H4 in glioma
immunotherapy or even other brain metastasis tumors
still deserves further research using larger clinical immunotherapy trials and concurrent functional studies, as
well as the studies exploring development of anti-B7-H4
immunotherapy protocols. PD-
L1/B7-
H4 signatures
demonstrated an underlying association with specific
relevant immune phenotype classification in gliomas.
Conclusions
In summary, we assessed the expression patterns of
PD-L1 and B7-H4 in a large cohort of glioma patients
and found mutually exclusive associations between them,
which is helpful to decipher prominent and nonoverlapping immune escape pathways. Identification of PD-L1/
B7-H4-related gene coexpression modules may be useful
to define new subtypes of gliomas and elucidating molecular mechanisms underlying tumor immune escape.
We found B7-H4 expression negatively correlated with
TILs presence which indicated that B7-H4 might inhibit
T-cell trafficking into the CNS. Distinct immune microenvironment profiles between PD-
L1/B7-
H4 modules
Chen D, et al. J Immunother Cancer 2020;8:e000154. doi:10.1136/jitc-2019-000154

offers a promising avenue for the development of glioma
immunotherapy strategies using PD-
L1 and B7-
H4 as
biomarkers. Future studies are needed to uncover underlying biological mechanisms for alternative immune regulatory checkpoints and clinically useful biomarkers such
as B7-H4, especially in gliomas with low expression of
PD-L1.
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